LMNGF News and Press, BioVaxys Technology From 03/24/21

BioVaxys Expands Intellectual Property Portfolio Canada NewsWire - Patent Filing To Address Emerging SARS-CoV-2 Variants - National Phase Filings For Cancer Vaccine VANCOUVER, BC , March 24, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) ...

Palm Beach, FL – March 18, 2021 – While most of the world press has been focused on the vaccine development and implementation, that is not the whole story. Numerable collaborations between governments, test developers, public health organizations, and private laboratories hav...

BioVaxys Enters Agreement With Inotiv To Conduct Preclinical Toxicity Studies For Its Covid-T™ Immunodiagnostic Program Canada NewsWire VANCOUVER, BC , March 18, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ( "BioVaxys"),...

Palm Beach, FL – March 15, 2021 – The recent pandemic, in one way, is like the WWIII we were hoping would never come. The whole world is fighting…  not against each other, but against a common enemy. Never has there been a conflict where all nations are seeking to ...

BioVaxys Enters Major Bioproduction Agreement With Wuxi Biologics (Hong Kong) Ltd. To Synthesize Proteins For Its SARS-CoV-2 Vaccine And COVID-T™ Immunodiagnostic Programs Canada NewsWire VANCOUVER, British Columbia , March 15, 2021 /CNW/ -- BioVaxys Techn...

Palm Beach, FL – March 1, 2021 – The epic global race to solve the COVID-19 crisis has just gotten a be a more of a puzzle with the emergence of new variants. The existing vaccines have been based on research centered on the original virus but the variants are raising question...

BioVaxys Expanding Technology Platform To Address Emerging SARS-CoV-2 Variants BVX-0320 and Covid-T to have capability to address UK, Brazilian and South African Virus Variants Canada NewsWire VANCOUVER, B.C. , March 1, 2021 /CNW/ -- BioVaxys Technology Cor...

BioVaxys Announces Appointment To Its Scientific Advisory Board PR Newswire VANCOUVER, B.C. , Feb. 22, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys"), a biotechnology company that is advancing viral and onc...

Palm Beach, FL – February 18, 2021 – Ovarian cancer and its rising incidence rate is a growing concern worldwide and the rising incidence of ovarian cancer will be driving the ovarian cancer drugs market for years to come. Ovarian cancer is regarded as one of the most common t...

BioVaxys and BioElpida Sign Term Sheet for Clinical Grade BVX-0918A Bio-production Canada NewsWire SIGNIFICANT ADVANCEMENT TOWARDS LAUNCH OF PHASE I OVARIAN CANCER VACCINE TRIAL VANCOUVER, BC , Feb. 18, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) ...